XTSX
AVCR
Market cap5mUSD
Jul 23, Last price
0.08CAD
1D
-6.25%
1Q
36.36%
Jan 2017
-65.91%
IPO
-81.25%
Name
Avricore Health Inc
Chart & Performance
P/E
—
P/S
2.18
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.07%
Rev. gr., 5y
72.76%
Revenues
3m
+97.08%
Net income
-701k
L-15.17%
CFO
660k
P
Earnings
Aug 27, 2025
Profile
Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,485 97.08% | 1,768 1,339.95% | |||||||
Cost of revenue | 4,126 | 2,493 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (640) | (725) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 8 | ||||||||
Tax Rate | |||||||||
NOPAT | (640) | (733) | |||||||
Net income | (701) -15.17% | (827) -52.67% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 42 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 40 | 40 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1 | ||||||||
Net debt | (247) | (591) | |||||||
| Cash flow | |||||||||
Cash from operating activities | 660 | (438) | |||||||
CAPEX | (1,022) | (1,199) | |||||||
Cash from investing activities | (1,047) | (1,209) | |||||||
Cash from financing activities | 42 | 254 | |||||||
FCF | (1,103) | (1,909) | |||||||
| Balance | |||||||||
Cash | 287 | 631 | |||||||
Long term investments | |||||||||
Excess cash | 112 | 542 | |||||||
Stockholders' equity | 2,009 | 1,964 | |||||||
Invested Capital | 1,937 | 1,411 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 99,559 | 97,859 | |||||||
Price | 0.32 96.88% | ||||||||
Market cap | 30,826 108.03% | ||||||||
EV | 30,235 | ||||||||
EBITDA | (220) | (542) | |||||||
EV/EBITDA | |||||||||
Interest | 8 | ||||||||
Interest/NOPBT | |||||||||